Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Stock Information for Purple Biotech Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Purple Biotech Ltd.

Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform
Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform
Purple Biotech Announces CEO Transition
Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results
Purple Biotech Announces Plan to Implement ADS Ratio Change
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.